feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouUnited StatesUnited States
You
bookmarksYour BookmarkshashtagYour Topics
Trending
Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2026 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

Home / Health / Lilly Pill: Weight Loss Convenience Ahead

Lilly Pill: Weight Loss Convenience Ahead

12 Jan

•

Summary

  • Eli Lilly is confident in supplies for its new weight-loss pill.
  • The drug, orforglipron, received FDA fast-track review, speeding approval.
  • Lilly's pill offers convenience over rivals by not requiring specific timing with food.
Lilly Pill: Weight Loss Convenience Ahead

Eli Lilly announced on Monday its confidence regarding the supply chain for its new weight-loss pill, orforglipron, in anticipation of its U.S. market approval in the coming months. The pharmaceutical giant is preparing for a swift international launch.

The drug has been granted a fast-track review by the U.S. Food and Drug Administration, a designation that could reduce the typical review period from ten to twelve months down to just one to two months. This expedited process signals a strong potential for a timely market entry.

Daniel Skovronsky, head of research and development at Eli Lilly, highlighted the pill's convenience as a key differentiator against competitors like Novo Nordisk. Unlike some existing weight-loss medications that require specific fasting conditions before administration, orforglipron can be taken at any time, independent of meals, offering patients greater flexibility.

trending

JPMorgan Chase earnings beat

trending

Patriots defeat Chargers 16-3

trending

Leafs beat Avalanche in OT

trending

Anthropic launches Claude for Healthcare

trending

Clippers beat Hornets

trending

Red Wings honor Fedorov

trending

Kings beat Los Angeles Lakers

trending

Emma Raducanu Hobart debut

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
Eli Lilly's new weight-loss pill is called orforglipron.
Orforglipron offers greater convenience as it can be taken at any time, unaffected by food, unlike Novo Nordisk's pill which requires fasting.
Eli Lilly is confident in supplies ahead of its anticipated U.S. approval in the coming months, with a fast-track review potentially speeding up the process.

Read more news on

Healthside-arrow

You may also like

Millions of Australians May Soon Access Subsidized Wegovy

1 day ago • 11 reads

article image

FDA Approves Oral Wegovy: Game Changer for Dieters?

23 Dec, 2025 • 165 reads

article image

Drugmakers Cut Prices After Trump Deal

20 Dec, 2025 • 113 reads

article image

Pharma Giant Hits Trillion-Dollar Mark

22 Nov, 2025 • 250 reads

article image

Novo Nordisk Cuts Prices on Wegovy and Ozempic by 30% in the US

18 Nov, 2025 • 239 reads

article image